On July 31, 2025, China\u2019s National Medical Products Administration (NMPA) commenced soliciting public comments on the “Regulations on the Filing Administration of Internet Drug and Medical Device Information Services (Draft for Comment).” The consultation period is open until August 30, inviting stakeholders and the public to provide feedback on the proposed regulatory framework.<\/p>\n\n\n\n
Scope and Regulatory Framework<\/strong> Requirements for Service Providers<\/strong><\/p>\n\n\n\n Filing Number Display<\/strong> Information Accuracy<\/strong> Prohibited Information<\/strong>
The draft regulations pertain to the provision of drug and medical device information services to internet users within the People\u2019s Republic of China. The NMPA will oversee and guide these activities at the national level, while provincial, autonomous region, and municipal drug regulatory departments will manage filing and supervision within their jurisdictions.<\/p>\n\n\n\n
Websites and mobile applications offering these services must prominently and continuously display their internet drug and medical device information service filing number on their homepage.<\/p>\n\n\n\n
Published drug and medical device information must be truthful, accurate, complete, and in compliance with national regulations.<\/p>\n\n\n\n
Service platforms are prohibited from publishing product information for:<\/p>\n\n\n\n